Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial.
Kristen SweetBidisha DasguptaDick de VriesIan GourleyBenjamin HsuMatthew J LozaPeter C TaylorPublished in: Annals of the rheumatic diseases (2019)
Keyphrases
- phase iii
- open label
- clinical trial
- rheumatoid arthritis
- phase ii
- magnetic resonance imaging
- double blind
- juvenile idiopathic arthritis
- placebo controlled
- blood flow
- hidradenitis suppurativa
- ultrasound guided
- study protocol
- randomized controlled trial
- computed tomography
- systemic lupus erythematosus
- disease activity